Female cancer prediction using cervical omics to individualise screening and prevention

Información del proyecto

FORECEE

Identificador del acuerdo de subvención: 634570

DOI 10.3030/634570

Proyecto cerrado

Fecha de la firma de la CE 27 Marzo 2015

Fecha de inicio 1 Septiembre 2015

Fecha de finalización 29 Febrero 2020

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total € 7 994 746,25

Aportación de la UE € 7 994 746,25

Coordinado por

UNIVERSITY COLLEGE LONDON
United Kingdom

Resultado final

Documents, reports (6)

Recommendations for screening policy from legal/regulatory/ethical and women’s perspective
Review on decision-analytic cost-effectiveness

Review on decision-analytic cost-effectiveness studies in women’s cancers (based on current screening/prevention strategies) analysis publication available

Cost-effectiveness in women’s cancer (based on WID test projections) analysis publication available
Leaflet and results from survey and public workshop results
Screening/prevention recommendations based on the WID test available
Scientific publication on the optimal delivery of risk-stratified screening, including consensus guidelines on implementation plan

Websites, patent fillings, videos etc. (3)

Project website
Multimedia presentation available
Formal presentation to the ESGO patient advocacy group (ENGAGe)

Formal presentation to the ESGO patient advocacy group ENGAGe

Publicaciones

Peer reviewed articles (7)

Epigenetic Discrimination: Emerging Applications of Epigenetics Pointing to the Limitations of Policies Against Genetic Discrimination

Autores: Charles Dupras, Lingqiao Song, Katie M. Saulnier, Yann Joly
Publicado en: Frontiers in Genetics, Edición 9, 2018, ISSN 1664-8021
Editor: Frontiers Media
DOI: 10.3389/fgene.2018.00202

Prediction models for endometrial cancer for the general population or symptomatic women: A systematic review

Autores: Maaike Alblas, Kimberley B. Velt, Nora Pashayan, Martin Widschwendter, Ewout W. Steyerberg, Yvonne Vergouwe
Publicado en: Critical Reviews in Oncology/Hematology, Edición 126, 2018, Página(s) 92-99, ISSN 1040-8428
Editor: Elsevier BV
DOI: 10.1016/j.critrevonc.2018.03.023

Ethical, Legal, and Regulatory Issues for the Implementation of Omics-Based Risk Prediction of Women’s Cancer: Points to Consider

Autores: Emmanuelle Lévesque, Emily Kirby, Ineke Bolt, Bartha Maria Knoppers, Inez de Beaufort, Nora Pashayan, Martin Widschwendter
Publicado en: Public Health Genomics, 2018, Página(s) 1-8, ISSN 1662-4246
Editor: S. Karger AG
DOI: 10.1159/000492663

Epigenome-based cancer risk prediction: rationale, opportunities and challenges

Autores: Martin Widschwendter, Allison Jones, Iona Evans, Daniel Reisel, Joakim Dillner, Karin Sundström, Ewout W. Steyerberg, Yvonne Vergouwe, Odette Wegwarth, Felix G. Rebitschek, Uwe Siebert, Gaby Sroczynski, Inez D. de Beaufort, Ineke Bolt, David Cibula, Michal Zikan, Line Bjørge, Nicoletta Colombo, Nadia Harbeck, Frank Dudbridge, Anne-Marie Tasse, Bartha M. Knoppers, Yann Joly, Andrew E. Teschendorf
Publicado en: Nature Reviews Clinical Oncology, Edición 15/5, 2018, Página(s) 292-309, ISSN 1759-4774
Editor: Nature Publishing Group
DOI: 10.1038/nrclinonc.2018.30

What do European women know about their female cancer risks and cancer screening? A cross-sectional online intervention survey in five European countries

Autores: Odette Wegwarth, Martin Widschwendter, David Cibula, Karin Sundström, Rosalba Portuesi, Ines Lein, Felix G Rebitschek
Publicado en: BMJ Open, Edición 8/12, 2018, Página(s) e023789, ISSN 2044-6055
Editor: BMJ Publishing Group
DOI: 10.1136/bmjopen-2018-023789

Integration of genetic and epigenetic markers for risk stratification: opportunities and challenges

Autores: Nora Pashayan, Daniel Reisel, Martin Widschwendter
Publicado en: Personalized Medicine, Edición 13/2, 2016, Página(s) 93-95, ISSN 1741-0541
Editor: Future Medicine Ltd.
DOI: 10.2217/pme.15.53

Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management

Autores: Vit Weinberger, Marketa Bednarikova, David Cibula, Michal Zikan
Publicado en: Expert Review of Anticancer Therapy, Edición 16/12, 2016, Página(s) 1311-1321, ISSN 1473-7140
Editor: Future Drugs Ltd.
DOI: 10.1080/14737140.2016.1247699

Non-peer reviewed articles (1)

Autonomy Challenges in Epigenetic Risk-Stratified Cancer Screening: How Can Patient Decision Aids Support Informed Consent?

Autores: Maaike Alblas, Maartje Schermer, Yvonne Vergouwe, Ineke Bolt
Publicado en: Journal of Personalized Medicine, Edición 9/1, 2019, Página(s) 14, ISSN 2075-4426
Editor: Jourmal of Personalized Medicine
DOI: 10.3390/jpm9010014